ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

IL2

interleukin 2 · also IL-2, TCGF · Interleukins

7 programs in company-led studies act on IL2, from 5 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
daromunrulePhilogen–phase 366 running–NCIt
darleukinrulePhilogen–phase 395 running–NCIt
Daxokafusp AlfaSanofi–phase 222 runningIL15, PDCD1a judged reading
SAR444336Sanofi–phase 221 running–the company's pipeline
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industries–phase 122 runningPDCD1the company's pipeline
IL-2 Mutein/Fc Fusion Protein HM16390ruleHanmi Pharmaceutical–phase 111 running–NCIt
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleOutpace Bio–phase 110 runningEGFR, MSLNNCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.